Free Trial
NYSE:SQZ

SQZ Biotechnologies (SQZ) Stock Price, News & Analysis

SQZ Biotechnologies logo
$0.03 0.00 (0.00%)
As of 07/25/2025

About SQZ Biotechnologies Stock (NYSE:SQZ)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.03
$0.04
52-Week Range
$0.25
$3.56
Volume
N/A
Average Volume
455,220 shs
Market Capitalization
$825.75 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive SQZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SQZ Stock News Headlines

SQZB SQZ Biotechnologies Company - Seeking Alpha
SQZ Biotechnologies Co Ordinary Shares
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
SQZ Biotechnologies Company (SQZB)
Sqz Bio (SQZB) Earnings Dates & Reports
VC funding update: who raised money in March?
See More Headlines

SQZ Stock Analysis - Frequently Asked Questions

SQZ Biotechnologies' stock was trading at $0.03 at the beginning of 2025. Since then, SQZ stock has decreased by 6.7% and is now trading at $0.0280.

SQZ Biotechnologies (NYSE:SQZ) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($8.00) earnings per share for the quarter, missing the consensus estimate of ($5.60) by $2.40. The company earned $4.76 million during the quarter, compared to analyst estimates of $11.64 million. SQZ Biotechnologies had a negative net margin of 369.96% and a negative trailing twelve-month return on equity of 119.83%.

Shares of SQZ Biotechnologies reverse split on the morning of Friday, July 7th 2023.The 1-10 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

SQZ Biotechnologies (SQZ) raised $75 million in an IPO on Friday, October 30th 2020. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Securities and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Shares of SQZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SQZ Biotechnologies investors own include Minerva Neurosciences (NERV), Illumina (ILMN), NVIDIA (NVDA), Oramed Pharmaceuticals (ORMP), Absci (ABSI), Allogene Therapeutics (ALLO) and Beam Therapeutics (BEAM).

Company Calendar

Last Earnings
11/10/2021
Today
7/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Transportation
Current Symbol
NYSE:SQZ
CIK
1604477
Fax
N/A
Employees
1,620
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79.46 million
Net Margins
-369.96%
Pretax Margin
-408.99%
Return on Equity
-119.83%
Return on Assets
-59.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.50
Quick Ratio
3.50

Sales & Book Value

Annual Sales
$18.16 million
Price / Sales
0.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.94 per share
Price / Book
0.01

Miscellaneous

Outstanding Shares
29,491,000
Free Float
24,772,000
Market Cap
$825.75 thousand
Optionable
Not Optionable
Beta
2.34

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:SQZ) was last updated on 7/27/2025 by MarketBeat.com Staff
From Our Partners